Description
The arrival of the aromatase inhibitors (AIs) has increased the options available for the management of postmenopausal women with hormone sensitive breast cancer. Where and when we should use them is however still controversial with the many trials of their use often having raised more questions than they have answered. There is no doubt that they have a role to play but it will be quite some time before we can confidently answer the questions of whether all post menopausal breast cancer patients should get them and if not all, then which patients should get them and for how long
